Skip to main content
. 2025 Jan 3;10(1):104089. doi: 10.1016/j.esmoop.2024.104089

Table 2.

Analysis of factors predicting survival in 196 molecularly profiled end-stage cancer patients

Variable Stratum Number Univariate analysis
 Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Target and treatment subgroup No target 113 Ref Ref
Treated targeted 30 0.46 (0.28-0.74) 0.002 0.43 (0.26-0.73) 0.001
Untreated target 53 1.01 (0.72-1.43) 0.94 0.94 (0.64-1.39) 0.73
Age (years) 196 1.00 (0.99-1.01) 0.98
Gender Female 112 Ref
Male 84 1.17 (0.86-1.60) 0.31
Histology Othera 33 Ref Ref
AdC 125 0.48 (0.32-0.72) <0.001 0.52 (0.32-0.82) 0.005
SCC 14 0.48 (0.23-0.97) 0.04 0.6 (0.27-1.34) 0.21
Glioma 24 0.62 (0.36-1.06) 0.08 0.92 (0.27-3.17) 0.9
Primary site Otherb 63 Ref Ref
Breast 26 0.60 (0.37-0.99) 0.04 1.24 (0.69-2.23) 0.47
Lung 30 0.76 (0.47-1.25) 0.29 1.01 (0.59-1.72) 0.98
Ovaries 27 0.66 (0.40-1.09) 0.10 1.01 (0.58-1.77) 0.98
Brain 27 0.87 (0.54-1.39) 0.56 0.7 (0.19-2.53) 0.58
Prostate 23 0.70 (0.41-1.17) 0.17 1.33 (0.7-2.49) 0.38
Time from diagnosis (months)c 196 0.99 (0.99-1.00) 0.002 0.99 (0.99-1.00) 0.003
Number of metastatic sitesd 196 1.14 (1.01-1.29) 0.04 1.18 (1.02-1.38) 0.03
Metastatic sitese Other 131 Ref
Liver 65 1.27 (0.92-1.75) 0.14
Other 142 Ref
Lung 54 1.13 (0.80-1.59) 0.49
Other 144 Ref
Bone 52 0.92 (0.65-1.29) 0.63
Other 106 Ref
Distant lymph nodes 90 0.99 (0.73-1.34) 0.92
ECOG PS 0 92 Ref Ref
1 93 0.96 (0.70-1.31) 0.79 0.82 (0.56-1.2) 0.31
2 11 2.85 (1.50-5.42) 0.001 1.42 (0.7-2.86) 0.33
Number of prior systemic treatment regimens 196 0.99 (0.92-1.07) 0.85
Prior high-dose radiotherapy No 151 Ref
Yes 45 1.00 (0.70-1.43) 0.98
BMI 194 0.97 (0.94-1.00) 0.08
Smoking status Never 68 Ref
Current/former 106 1.33 (0.95-1.86) 0.10
Prior or concurrent other cancer No 160 Ref
Yes 36 0.70 (0.46-1.07) 0.10
Germline variant None 181 Ref
Undetermined 6 1.34 (0.55-3.27) 0.52
Present 9 0.62 (0.29-1.32) 0.22
Number of affected pathwaysf 110 1.04 (0.97-1.12) 0.25
RTK/RAS pathway Not affected 74 Ref Ref
Affected 115 1.61 (1.16-2.24) 0.004 1.81 (1.23-2.67) 0.003
PIK3 pathway Not affected 115 Ref
Affected 74 1.17 (0.85-1.61) 0.33
Cell cycle pathway Not affected 157 Ref
Affected 32 1.29 (0.86-1.93) 0.22
Myc pathway Not affected 170 Ref
Affected 19 0.85 (0.49-1.47) 0.55
Hippo pathway Not affected 107 Ref
Affected 82 0.87 (0.64-1.20) 0.40
Notch pathway Not affected 112 Ref
Affected 77 0.91 (0.66-1.25) 0.55
Nrf2 pathway Not affected 180 Ref
Affected 9 0.76 (0.36-1.63) 0.48
TGFβ pathway Not affected 170 Ref
Affected 19 1.49 (0.90-2.46) 0.13
P53 pathway Not affected 77 Ref
Affected 112 1.20 (0.87-1.65) 0.27
Wnt pathway Not affected 118 Ref
Affected 71 1.07 (0.77-1.47) 0.69
TMB-H No 157 Ref
Yes 30 1.30 (0.86-1.97) 0.20

AdC, adenocarcinoma; BMI, body mass index; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; MMR, mismatch repair; NMTB, National Molecular Tumor Board; ref, reference; SCC, squamous-cell carcinoma; TMB-H, tumor mutational burden high (>10 mutations per megabase).

a

‘Other histologies’ include neuroendocrine carcinoma, basal cell carcinoma, mesothelioma, carcinosarcoma, atypical meningioma, and transitional cell carcinoma.

b

‘Other primary sites’ include female genital tract excluding ovaries, esophagus-stomach, head-and-neck, skin, pancreas, and urinary tract.

c

Time from first diagnosis of cancer to date of NMTB.

d

The 31 patients with locally advanced disease are scored 0.

e

Patients may have more than one metastatic site. Rarer metastatic sites are not shown or tested.

f

Seven cases excluded: Data not available (four cases), high numbers of variants of low frequencies due to formalin fixation, prior treatment with temozolomide, and biallelic germline MMR gene mutation.